EGFR and head and neck squamous cell carcinoma: Cetuximab, a monoclonal antibody-inhibiting EGFR, is the only cancer-targeting agent approved for HNSCC, although only ~10% of HNSCC patients respond to this agent and often for a short period of time [4, 5].